Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial

Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The PRIME-HCC study record is displayed with its protocol document and detailed information about the trial’s design, participants, treatments, and outcomes.
    Difference
    56%
    Check dated 2026-11-07T11:32:46.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The displayed site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T11:33:12.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A notice about NIH websites transitioning from the term “artificial intelligence” to “super intelligence” appears above the 403 error page. The study record remains unavailable.
    Difference
    1%
    Check dated 2026-10-24T11:19:27.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T12:08:53.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The footer’s site revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T13:05:27.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The study details page now displays a 403 Forbidden error instead of the original content. This blocks users from viewing the trial's details and related information.
    Difference
    0.5%
    Check dated 2026-09-26T16:07:46.000Z thumbnail image

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.